PDCD1 and renal cell carcinoma: The immunogenic nature of RCC raised the prospect that immune checkpoint inhibitors (ICI), including anti-PD-1 antibodies (aPD1), could improve outcomes of those with advanced disease (Weinstock and McDermott, 2015; Rini et al., 2019).